Global Microbiome Therapeutics Market Report 2021 – Growth, Trend and Forecast to 2027. Uncategorized; Meta. Capital Fund Qualified Lp Ecor1 is the largest individual Assembly Biosciences shareholder, … Assembly Biosciences (ASMB) Reports Q1 Loss, Lags Revenue Estimates. Published. Their forecasts range from $8.00 to $15.00. On average, they expect Assembly Biosciences' stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 166.8% from the stock's current price. View analysts' price targets for Assembly Biosciences or view top-rated stocks among Wall Street analysts. Assembly Biosciences confirmed that it still expects to begin a pivotal late-stage study of VBR in the first half of 2021, evaluating the drug for chronic suppressive therapy. Assembly Biosciences, Inc. (ASMB) shares have jump down -71.31% during the last six months, with a year-to-date growth rate less than the industry average at -82.86% against -0.3%. A copy of the press release is attached hereto as Exhibit 99.1. $4.08 … 6B), indicating that ATG9B promotes FA assembly relied on MYH9 interaction. The company's filing status is listed as Active and its File Number is 604757730. Assembly Biosciences Inc. [NASDAQ: ASMB] closed the trading session at $4.37 on 04/22/21. This compares to year-ago revenues of $4.08 million. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.10. Date of Earliest Transaction (MM/DD/YYYY) 5/20/2021 (Street) SOUTH SAN FRANCISCO, CA 94080 (City) (State) (Zip) 4. NASDAQ. On May 6, 2021, Assembly Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2021. ASMBAssembly Biosciences IncCompare. SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent updates for the first quarter ended March 31, 2021. Assembly Biosciences (ASMB) reported a 1st Quarter March 2021 loss of $0.69 per share on revenue of $0.0 million. Log in; Entries feed; Comments feed; WordPress.org Assembly Biosciences, Inc. is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Fiscal Year End Dec 31, 2021. Assembly Biosciences (NASDAQ: ASMB) was reported by SVB Leerink on 2021-05-10. ... Price as of June 14, 2021, 4:00 p.m. In comparing Assembly Biosciences Inc. (ASMB)’s stock with other industry players reveals that stock’s current price change of -2.64% and that of -81.60% over the past 12 months is in competing position with that of Ironwood Pharmaceuticals Inc. (IRWD) which saw its stock price raised by 2.18% in the last trading and went through an increase of 17.43% in past 12-month trading. Assembly Biosciences Inc real time quote is equal to 4.110 USD at 2021-06-16, but your current investment may be devalued in the future. Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to six new employees to purchase an aggregate … Fiscal Year End Dec 31, 2021. The sum of our individual differences, life experiences, knowledge, inventiveness, innovation, self-expression, capabilities and talent represents a significant part of our culture and ties directly to our achievements as a company. Assembly Biosciences Inc. (NASDAQ:ASMB) went down by -2.05% from its latest closing price compared to the recent 1-year high of $27.84. Archives. Assembly Biosciences is headquartered at 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. How can I contact Assembly Biosciences? The company’s stock price has collected -1.83% of loss in the last five trading sessions. SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that three abstracts have been accepted for presentation during the International Liver Congress™ 2021, the Annual Meeting of the European … Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 12.66% and -100.00%, respectively, for the quarter ended March 2021. The average estimate of four analysts surveyed by Zacks Investment Research was for … Most Recent Earnings Mar 31, 2021. The day’s price range saw the stock hit a low of $4.12, while the highest price level was $4.43. SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to six new employees to purchase an aggregate of 106,520 shares of the Company's common stock with an … Assembly Biosciences has generated ($1.75) earnings per share over the last year. Per-share losses are expected to explode, reaching US$3.21 per share. Assembly Bio is committed to fostering, cultivating, and preserving a culture of diversity and inclusion. So it sure is nice to see a bit of an improvement. Current Price: 4.110 USD : 000000000 | State of Incorp. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for. Assembly Biosciences (ASMB) Reports Q1 Loss, Lags Revenue Estimates. acheter XRP Saint-Siège 2021; NV5 Global Inc Perú 2021; acheter XRP République tchèque 2021; Capitala Finance Corp Perú 2021; Agios Pharm Perú 2021; Recent Comments. Real time Assembly Biosciences (ASMB) stock price quote, stock graph, news & analysis. Revenue fell 100.0% compared to the same quarter a year ago. The company report on March 6, 2021 that Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Ru : The company reported the previous year's revenue of 75.02 M.Net Loss for the year was (62.7 M) with loss before overhead, payroll, taxes, and interest of (22.23 M). Uncategorized; Meta. May 24, 2021 Dr. Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors “It’s time to end the deadly Hepatitis B virus that has killed more than 800,000 people … Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 12.66% and -100.00%, respectively, for the quarter ended March 2021. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Yet analysts are winding down their growth forecast for the fiscal year 2021. Stock Type … But that is meagre solace in the face of the shocking decline over three years. The stock current value is $4.17. Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021 SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that three abstracts have … Ticker: ASMB. The consensus estimate was a loss of $0.79 per share on revenue of $2.5 million. The company has topped consensus revenue estimates two times over the last four quarters. Assembly Biosciences Inc, formerly Ventrus Biosciences Inc, is a pharmaceutical company. A ssembly Biosciences (ASMB) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a … The Registered Agent on file for this company is John Gunderson and is located at 905 Se 98th Ave, Vancouver, WA 98664. Assembly Biosciences last posted its quarterly earnings results on May 5th, 2021. Following the latest downgrade, the current consensus, from the six analysts covering Assembly Biosciences, is for revenues of US$6.6m in 2021, which would reflect a substantial 92% reduction in Assembly Biosciences' sales over the past 12 months. ASMB 4.17 0.06 (1.46%). Assembly Biosciences Inc stock is lower by -67.95% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives ASMB stock a score of 34 out of a possible 100.. That rank is chiefly influenced by a long-term technical score of 1. The consensus estimate was a loss of $0.79 per share on revenue of $2.5 million. Assembly Biosciences (ASMB) reported a 1st Quarter March 2021 loss of $0.69 per share on revenue of $0.0 million. Revenue is the top line item on an income statement from which all costs and … Chapter 1 Microbiome Therapeutics Market Overview. Press Release reported on 03/05/21 that Assembly Biosciences Reports Ind Assembly Biosciences Groton, CT Photos. Description: Assembly Biosciences Inc is a clinical-stage biotechnology company. Cash, cash equivalents and marketable securities were $214.9 million as of March 31, 2021, compared to $216.4 million as of December 31, 2020. May 2021; December 2020; Categories. Assembly Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021. View our earnings forecast for Assembly Biosciences. How were Assembly Biosciences' earnings last quarter? Assembly Biosciences, Inc. (NASDAQ:ASMB) announced its earnings results on Thursday, February, 25th. Assembly Biosciences Inc, formerly Ventrus Biosciences Inc, is a pharmaceutical company. Assembly Biosciences 2021-01-25 12:48 PST. Assembly Biosciences, Inc is primarely in the business of pharmaceutical preparations. The share price has sunk like a leaky ship, down 86% in that time. Assembly Biosciences net income from 2010 to 2021. Assembly Biosciences, which belongs to the Zacks Medical - Generic Drugs industry, posted zero revenues for the quarter ended March 2021, missing the Zacks Consensus Estimate by 100%. March 5, 2021 - 5:00 pm. Share a Photo. Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress(TM) EASL 2021 June 10, 2021 | marketwatch.com Zacks: Analysts Expect Assembly Biosciences, Inc. (NASDAQ:ASMB) Will Announce Quarterly Sales of $2.51 Million Overall market sentiment has been high on Assembly Biosciences Inc stock lately. Aura Biosciences, Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The Report also calculates the market size, Microbiome Therapeutics Sales, Price, Revenue, Gross … powered by Microsoft News. Assembly Biosciences (NASDAQ: ASMB) news for Friday includes information from its third quarter of 2020 dropping ASMB stock. However, it’s not actually the results that are hurting the company, as it beat out estimates for the quarter. Instead, the issue has to do with clinical trial results included in the report. Do NOT follow this link! SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent updates for the first quarter ended March 31, 2021. SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 26,000 … It only takes a second, and your photos are anonymous. Assembly Biosciences (NASDAQ: ASMB) is owned by 71.59% institutional shareholders, 14.88% Assembly Biosciences insiders, and 13.53% retail investors. SOUTH SAN FRANCISCO, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 25,000 shares of the Company’s common stock with an … In-depth view of key statistics and finances for ASSEMBLY BIOSCIENCES, INC. (ASMB) on MSN Money. May 24, 2021 Dr. Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors PR Newswires. The latest price target for . The analyst firm set a price … Do the numbers hold clues to what lies ahead for the stock? This … Issuer Name and Ticker or Trading Symbol ASSEMBLY BIOSCIENCES, INC. [ASMB] (Last) (First) (Middle) C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR June 18, 2021 At the end of the latest market close, Assembly Biosciences Inc. (ASMB) was valued at $4.11. Moreover, we found that overexpressing ATG9B Δ368-411 had no effect on FA assembly of CRC cells (Fig. ASSEMBLY BIOSCIENCES, INC. (Filer) CIK: 0001426800 (see all company filings) IRS No. Stock Type … Global “Microbiome Therapeutics Market” 2021-2028 Research Report provides key analysis on the market status of the Microbiome Therapeutics manufacturers with best facts and figures, meaning, definition, SWOT analysis, expert opinions and the latest developments across the globe. Assembly Biosciences last posted its quarterly earnings results on May 5th, 2021. US markets are open After hours trading starts in 1 hour. June 2021; May 2021; January 2021; December 2020; Categories. Most Recent Earnings Mar 31, 2021. Health Care. Assembly Biosciences revenue from 2010 to 2021. Assembly Biosciences NASDAQ Updated Jun 17, 2021 8:42 PM. Log in; Entries feed; Comments feed; WordPress.org : 000000000 | State of Incorp. 1. See All Reviews. Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 12.66% and -100.00%, respectively, for the quarter ended March 2021. Post-Market 0.02 (0.48%) C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR: 3. Assembly Biosciences, Inc. ( NASDAQ:ASMB) shareholders should be happy to see the share price up 26% in the last quarter. Assembly Biosciences has generated ($1.75) earnings per share over the last year. Get this page going by posting a photo. --Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today reported financial results and … “In the first quarter of 2021, we solidified all our efforts and focus … The Report also calculates the market size, Microbiome Therapeutics Sales, Price, Revenue, Gross … Get directions, reviews and information for Assembly Biosciences, Inc in South San Francisco, CA. Wednesday, June 09, 2021 02:54 PM | InvestorsObserver Analysts. Assembly Biosciences Inc has a Bullish sentiment reading. Name and Address of Reporting Person * Samar Michael P.: 2. May 6 (Reuters) - Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND RECENT UPDATES * Q1 LOSS PER SHARE $0.69 * Q1 EARNINGS PER SHARE VIEW $-0.79-- REFINITIV IBES DATA Source text for Eikon: Further company coverage: Biotechnology. Regular trading. ... Last updated time 4/19/2021 … ASSEMBLY BIOSCIENCES, INC. (Filer) CIK: 0001426800 (see all company filings) IRS No. For financial reporting, their fiscal year ends on December 31st. ASMB's rank also includes a short-term technical score of 3. msn back to msn home money. Date of Event Requiring Statement (MM/DD/YYYY) 6/4/2021 : 3. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.10. Assembly Biosciences Groton, CT employees haven't posted any photos yet. ASMB receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator. Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights Content Import Thu, 02/25/2021 - 16:06 Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights February 25, 2021 … Assembly Biosciences Inc Brasil 2021; Oxford Lane Capital Corp Chile 2021; Leggett & Platt Incorporated Perú 2021; CMS Energy Corporation Brasil 2021; DuPont Inc Perú 2021; Recent Comments. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Assembly Biosciences generates negative expected return over the last 90 days: Assembly Biosciences was previously known as Assembly Biosciences and was traded on NASDAQ Exchange under the symbol VTUS. ET View Interactive ASMB Charts. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person Press Release reported on 06/09/21 that Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress (TM) EASL 2021 Get the hottest stocks to trade every day before the market opens 100% free. 5 Stocks Under $10 That Are Poised to Take Off Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Global “Microbiome Therapeutics Market” 2021-2028 Research Report provides key analysis on the market status of the Microbiome Therapeutics manufacturers with best facts and figures, meaning, definition, SWOT analysis, expert opinions and the latest developments across the globe. SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to six new employees to purchase an aggregate of 106,520 shares of the Company’s common stock with an … In that particular session, Stock kicked-off at the price of $4.11 while reaching the peak value of $4.26 and lowest value recorded on the day was $4.03. Revenue fell 100.0% compared to the same quarter a year ago. In Q1 2021 Assembly Bio completed the previously announced winddown of its microbiome program. documents---0.0013089179992676. Assembly Biosciences Inc. (ASMB): The stock short term indicators say Sell today ... June 16, 2021 How have the shares performed? Assembly Biosciences Inc. (ASMB) shares have gone down -28.06% during the last six months, with a year-to-date growth rate less than the industry average at -48.57% against 5.10. Dr. Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors. Archives. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Feb 25, 2021 7:10PM EST. Assembly Biosciences, Inc. is a Washington Foreign Profit Corporation filed On May 18, 2021. February 05, 2021. MAY 6, 2021 - SOUTH SAN FRANCISCO, Calif. (AP) _ Assembly Biosciences Inc. (ASMB) on Thursday reported a loss of $27.2 million in its first quarter.The South San Francisco, California-based company said it had a loss of 69 cents per share.The results beat Wall Street expectations.